Skip to main content
AAN.com

Abstract

We related the histopathologic changes associated with incidental white matter signal hyperintensities on MRIs from 11 elderly patients (age range, 52 to 82 years) to a descriptive classification for such abnormalities. Punctate, early confluent, and confluent white matter hyperintensities corresponded to increasing severity of ischemic tissue damage, ranging from mild perivascular alterations to large areas with variable loss of fibers, multiple small cavitations, and marked arteriolosclerosis. Microcystic infarcts and patchy rarefaction of myelin were also characteristic for irregular periventricular high signal intensity. Hyperintense periventricular caps and a smooth halo, however, were of nonischemic origin and constituted areas of demyelination associated with subependymal gliosis and discontinuity of the ependymal lining. Based on these findings, our classification appears to reflect both the different etiologies and severities of incidental MRI signal abnormalities, if it is modified to treat irregular periventricular and confluent deep white matter hyperintensities together.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 43Number 9September 1993
Pages: 1683
PubMed: 8414012

Publication History

Published online: September 1, 1993
Published in print: September 1993

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

F. Fazekas, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
R. Kleinert, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
H. Offenbacher, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
R. Schmidt, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
G. Kleinert, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
F. Payer, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
H. Radner, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.
H. Lechner, MD
Department of Neurology (Drs. Fazekas, Offenbacher, Schmidt, G. Kleinert, Payer, and Lechner), Magnetic Resonance Institute (Drs. Fazekas, Offenbacher, Schmidt, Payer, and Lechner), and Institute of Pathology, Laboratory of Neuropathology (Drs. R. Kleinert and Radner), Karl-Franzens University, Graz, Austria.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Leukoaraiosis: Epidemiology, Imaging, Risk Factors, and Management of Age-Related Cerebral White Matter Hyperintensities, Journal of Stroke, 26, 2, (131-163), (2024).https://doi.org/10.5853/jos.2023.02719
    Crossref
  2. Specialized gray matter segmentation via a generative adversarial network: application on brain white matter hyperintensities classification, Frontiers in Neuroscience, 18, (2024).https://doi.org/10.3389/fnins.2024.1416174
    Crossref
  3. Development and validation of a diagnostic model for cerebral small vessel disease among rural older adults in China, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1388653
    Crossref
  4. Development and validation of a predictive model for severe white matter hyperintensity with obesity, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1404756
    Crossref
  5. Distinct patterns of white matter hyperintensity and cortical thickness of CSF1R-related leukoencephalopathy compared with subcortical ischemic vascular dementia, PLOS ONE, 19, 10, (e0308989), (2024).https://doi.org/10.1371/journal.pone.0308989
    Crossref
  6. Whole exome sequencing in a sample of Egyptian patients with covert cerebral small vessel disease, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 60, 1, (2024).https://doi.org/10.1186/s41983-024-00810-2
    Crossref
  7. Interactive effect of diabetes mellitus and subclinical MRI markers of cerebrovascular disease on cognitive decline and incident dementia: a memory-clinic study, Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01577-7
    Crossref
  8. Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders, Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01536-2
    Crossref
  9. A promising frontier: targeting NETs for stroke treatment breakthroughs, Cell Communication and Signaling, 22, 1, (2024).https://doi.org/10.1186/s12964-024-01563-4
    Crossref
  10. Association of novel lipid indices with the white matter hyperintensities in cerebral small vessel disease: a cross-sectional study, Lipids in Health and Disease, 23, 1, (2024).https://doi.org/10.1186/s12944-024-02318-3
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share